GleamWall
中文EN

INO INOVIO PHARMACEUTICALS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1055726 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-70.0%
TTM net income YoY20.8%
TTM EPS YoY54.2%
Revenue 3-yr CAGR-81.5%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-132,871.3%
Net margin-130,000.0%
FCF margin-136,074.5%
EBITDA margin-130,701.4%

Returns

ROE-183.5%
ROA-90.6%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets67.6%
Debt / equity0.00x
Current ratio1.40x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.04x
Accruals ratio3.9%
Payout ratio—
Capex / revenue437.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$298,901$0$0$0$0$0$65,343$116,994
R&D expense$10.62M$10.83M$14.07M$10.26M$13.33M$14.52M$16.09M$12.89M
SG&A expense$9.21M$7.80M$7.88M$7.22M$7.88M$8.56M$9.02M$7.60M
Operating income-$19.52M-$18.62M-$21.95M-$17.48M-$21.21M-$23.08M-$25.05M-$20.37M
Interest expense———$0$0$0$0$0
Net income-$49.20M-$6.01M-$19.68M$3.76M-$45.50M-$23.52M-$19.69M-$19.38M
EBITDA-$19.20M-$18.30M-$21.63M-$17.14M-$20.86M-$22.73M-$24.68M-$19.95M
EPS (basic)-0.50-0.07-0.28—-0.87-0.61-0.51—
EPS (diluted)-0.50-0.07-0.28—-0.87-0.61-0.51—
Weighted avg. shares (diluted)98.63M81.62M69.10M—52.17M38.83M38.61M—
Balance sheet
Cash & equivalents$46.96M$31.53M$26.27M$44.27M$36.57M$24.35M$39.92M$65.81M
Short-term investments$1.40M$5.15M$11.41M$14.24M$14.24M$23.20M$28.45M$28.30M
Receivables———$450$978,590$840,312$1.31M$1.20M
Current assets$51.44M$39.91M$39.44M$61.12M$55.18M$52.70M$71.89M$97.83M
PP&E, net$1.57M$1.89M$2.21M$2.53M$2.74M$3.09M$3.35M$3.66M
Total assets$60.14M$49.39M$49.78M$74.31M$69.39M$68.24M$87.27M$113.20M
Current liabilities$89.47M$39.92M$37.92M$43.67M$69.82M$31.71M$27.33M$35.33M
Total liabilities$94.06M$45.02M$43.71M$50.21M$77.11M$39.71M$36.02M$44.69M
Shareholders' equity-$33.92M$4.37M$6.07M$24.10M-$7.72M$28.53M$51.25M$68.50M
Shares outstanding110.18M82.34M69.77M69.00M53.57M36.72M36.67M36.10M
Cash flow statement
Operating cash flow-$15.27M-$18.05M-$21.59M-$19.37M-$21.57M-$20.81M-$26.87M-$19.66M
Capital expenditure$0$0$0$127,444$67,951$30,930$59,373$0
Free cash flow-$15.27M-$18.05M-$21.59M-$19.50M-$21.64M-$20.84M-$26.93M-$19.66M
Investing cash flow$3.72M$6.15M$2.64M-$58,189$8.87M$5.28M-$51,753$34.64M
Financing cash flow$26.99M$17.16M$953,790$27.13M$24.92M-$34,777$1.03M$29.15M
Depreciation & amortization$322,034$322,034$316,844$340,197$350,198$356,151$371,367$416,821
Stock-based compensation$868,002$768,437$698,744$764,561$757,086$834,792$1.40M$1.32M

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.